Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations.
Bobbili PJ, Ivanova J, Solit DB, Mettu NB, McCall SJ, Dhawan M, DerSarkissian M, Arondekar B, Chang J, Niyazov A, Lee J, Huq R, Green M, Turski M, Lam P, Muthukumar A, Guo T, Mohan M, Zhang A, Duh MS, Oh WK. Bobbili PJ, et al. Among authors: arondekar b. Clin Genitourin Cancer. 2024 Jun;22(3):102080. doi: 10.1016/j.clgc.2024.102080. Epub 2024 Mar 23. Clin Genitourin Cancer. 2024. PMID: 38653037 Free article.
Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP. Mahtani R, et al. Among authors: arondekar b. Adv Ther. 2023 Jan;40(1):331-348. doi: 10.1007/s12325-022-02302-2. Epub 2022 Oct 28. Adv Ther. 2023. PMID: 36333567 Free PMC article.
Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Mahtani R, et al. Among authors: arondekar b. Breast. 2022 Dec;66:236-244. doi: 10.1016/j.breast.2022.10.009. Epub 2022 Oct 18. Breast. 2022. PMID: 36368161 Free PMC article.
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Mahtani R, et al. Among authors: arondekar b. BMC Cancer. 2022 Dec 22;22(1):1343. doi: 10.1186/s12885-022-10325-9. BMC Cancer. 2022. PMID: 36550413 Free PMC article.
Clinical characteristics, treatment patterns, and outcomes in adult patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States.
Obeid E, Parikh RC, Esterberg E, Arondekar B, Hitchens A, Arruda LS, Niyazov A, Whitaker K. Obeid E, et al. Among authors: arondekar b. Front Oncol. 2024 May 16;14:1341665. doi: 10.3389/fonc.2024.1341665. eCollection 2024. Front Oncol. 2024. PMID: 38817906 Free PMC article.
50 results